Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.
verywellhealth6d
Can You Outgrow Asthma?
The short answer is no, you cannot outgrow asthma, but your symptoms may be less severe. Learn when asthma goes into ...
Driving innovation in respiratory health: Areteia’s 2025 milestones and future goals
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Asthma and antibiotic use may predict nasal polyp recurrence after endoscopic sinus surgery
The probability of revision sinus surgery including removing nasal polyps is higher if the patient has asthma or is on ...
News Medical on MSN1d
Asthma and antibiotic use increase the likelihood of revision sinus surgery
The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...
Amgen's Broad Portfolio Strength and Wide Moat Should Protect Profits Despite Upcoming Biosimilars
Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...
Daily4d
GSK Depemokimab applications accepted for review in China, Japan for asthma with type 2 inflammation, CRSwNP
GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...
pharmaphorum5d
EU clears AstraZeneca's new-form severe asthma drug Tezspire
The green light for the pre-filled, single-use pen version of Tezspire (tezepelumab) comes just four months after the TSLP inhibitor became the first biologic therapy for severe asthma to be ...
Pharmabiz1d
Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis
Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...